Cordis acquires MedAlliance for up to $1.135 billion

Cordis announced the acquisition of MedAlliance, a Swiss developer of drug-eluting balloons. The deal includes an initial $35M investment, $200M payment upon closing in 2023, and up to $900M in regulatory and commercial milestones through 2029.

“The acquisition of MedAlliance illustrates our vision to maximize patient impact by pairing highly innovative growth drivers with Cordis’ trusted brand and extensive global commercial capabilities.”cordis.com

• 1 source
• cordis.comCordis | Cordis Announces Acquisition of MedAllianceOct 17, 2022

Summarized from public sources; check the original articles before acting on it.